Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Tart Cherry, Metabolic Syndrome, and Cardiovascular Risk

Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Link salvestatakse lõikelauale
StaatusValmis
Sponsorid
Florida State University
Kaastöötajad
Cherry Research Committee

Märksõnad

Abstraktne

The hypothesis of this study is that the daily consumption of 480 ml tart cherry juice for twelve weeks will improve blood pressure and arterial stiffness by improving endothelial-mediated vasodilation and vascular sympathetic activity and favorably altering biochemical markers associated with cardiovascular risk. 28 men and women between the ages of 20 and 40 who have three of the five features of metabolic syndrome as defined by the Adult Treatment Panel III will be included in the study. After a two-week run-in phase, eligible men and women will be randomly assigned to one of two treatment groups: 1) 480 ml tart cherry juice or 2) 480 ml control drink daily for twelve weeks. After an initial telephone screening, all participants will be requested to report to the study site for their first visit. On the first visit (screening), participants will be provided with verbal and written explanation of the project. They will then be asked to sign an informed consent form, followed by measuring waist circumference, resting brachial blood pressure, fasting serum triglycerides, high density lipoprotein cholesterol, and glucose levels to confirm metabolic syndrome. Baseline assessments will be performed for medical history, medication use, dietary intake, and physical activity. Qualified participants will be scheduled for their second visit two weeks later (actual baseline data collection) and randomly assigned to their treatment group. On the second (baseline) visit between the hours of 7-10 A.M., blood pressure and vascular function will be measured followed by blood draw. Anthropometrics will be measured. Participants will be provided with their assigned treatment and will receive standard instructions on how to fill out daily diaries for their treatment, and for food and physical activity records. Blood pressure, vascular function, blood draw, and anthropometric, body composition, diet, and physical activity assessments will be repeated at 6- (third visit), and 12-week (final visit) intervals. All cardiovascular measurements will be performed between 7:00 to 10:00 A.M., in a quiet temperature-controlled room in the supine position after an overnight fast and 12 hours after the abstinence of caffeine and/or 24 hours after the last bout of moderate to heavy physical activity.

Kuupäevad

Viimati kinnitatud: 11/30/2016
Esmalt esitatud: 05/29/2014
Hinnanguline registreerumine on esitatud: 05/29/2014
Esmalt postitatud: 06/02/2014
Viimane värskendus on esitatud: 12/05/2016
Viimati värskendus postitatud: 12/07/2016
Õppe tegelik alguskuupäev: 03/31/2014
Eeldatav esmane lõpetamise kuupäev: 09/30/2016
Eeldatav uuringu lõpetamise kuupäev: 09/30/2016

Seisund või haigus

Metabolic Syndrome
Cardiovascular Diseases
Diabetes

Sekkumine / ravi

Dietary Supplement: Tart Cherry

Dietary Supplement: Placebo

Faas

Faas 2

Käerühmad

ArmSekkumine / ravi
Experimental: Tart Cherry
12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Dietary Supplement: Tart Cherry
12 weeks of tart cherry juice taken in two doses of 240 ml per day.
Placebo Comparator: Placebo
12 weeks tart cherry juice taken in two doses of 240 ml per day.
Dietary Supplement: Placebo
12 weeks of tart cherry juice taken in two doses of 240 ml per day.

Abikõlblikkuse kriteeriumid

Õppimiseks sobivad vanused 20 Years To 20 Years
Uuringuks kõlblikud soodAll
Võtab vastu tervislikke vabatahtlikkeJah
Kriteeriumid

Inclusion Criteria:

- Three of the following five features at the screening visit:

- Waist circumference of ≥ 40 inches for men and 35 inches for women

- Serum triglycerides ≥ 150 mg/dL

- Serum high density lipoprotein cholesterol levels < 40 mg/dL for men and <50 mg/dL for women

- Blood pressure ≥ 130/85 mm Hg

- Fasting blood glucose level ≥ 110 mg/dL

Exclusion Criteria:

- Taking hypoglycemic, antihypertensive or cholesterol-lowering medications

- Diagnosed cardiovascular disease

- Uncontrolled hypertension (≥ 160/100 mmHg)

- Diabetes mellitus

- Other active chronic diseases such as cancer, asthma, glaucoma, thyroid, kidney, liver and pancreatic disease

- Participating in a weight loss program

- Heavy smokers (> 20 cigarettes per day)

- Heavy drinkers (> 12 alcoholic drinks per week)

- Abnormal menstrual cycle

Tulemus

Esmased tulemusnäitajad

1. Blood Pressure [12 weeks]

By measuring brachial and aortic blood pressure at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).

2. Arterial Stiffness [12 weeks]

By measuring arterial stiffness and augmentation index at rest and during physiological stress (handgrip exercise and post-exercise muscle ischemia).

Sekundaarsed tulemusmõõdud

1. Autonomic Control of Blood Pressure [12 weeks]

By measuring blood pressure variability and baroreflex sensitivity at rest and during physiological stress.

2. Endothelial Function [12 weeks]

By measuring markers of endothelial function.

3. Endothelial-mediated Vasodilation [12 weeks]

By measuring flow-mediated dilation in the brachial artery.

4. Inflammation [12 weeks]

By measuring a marker of inflammation.

5. Oxidative Stress [12 weeks]

By measuring markers of oxidative stress.

6. Insulin Sensitivity [12 weeks]

By measuring fasting glucose, insulin, and homeostatic model assessments of insulin resistance, sensitivity, and beta cell function.

7. Atherogenic Markers [12 weeks]

By measuring adhesion factors, lipid profiles, and atherogenic risk ratios.

8. Body Composition [12 weeks]

By measuring fat mass and fat-free mass using dual-energy X-ray absorptiometry and anthropometrics.

Liitu meie
facebooki lehega

Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus

  • Töötab 55 keeles
  • Taimsed ravimid, mida toetab teadus
  • Maitsetaimede äratundmine pildi järgi
  • Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
  • Lugege oma otsinguga seotud teaduspublikatsioone
  • Otsige ravimtaimi nende mõju järgi
  • Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega

Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel

Google Play badgeApp Store badge